Original Article
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study
Redefiniendo la retirada de omalizumab en pacientes con urticaria crónica espontánea: el valor de la optimización y de los biomarcadores de recurrencia
J. Ceravallsa,
, A.M. Giménez-Arnaub, V. Expósito-Serranoc, N. Fernández Chicoc, A. Lara Moyac, I. Bielsad, P. Ribóe, B. Mascaró-Herezae, M. Bonfill-Ortíf, J. Spertinog, E. Serrag, C. Baliu-Piquéh, G. Melé-Ninota
Autor para correspondencia
a Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo QuirónSalud, Barcelona, Catalonia, Spain
b Department of Dermatology, Hospital de Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain
c Department of Dermatology, Consorci Sanitari Parc Taulí, Sabadell, Catalonia, Spain
d Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Catalonia, Spain
e Department of Allergology, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain
f Department of Dermatology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Catalonia, Spain
g Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
h Department of Dermatology, Hospital d’Igualada-Consorci Sanitari de l’Anoia, Barcelona, Catalonia, Spain
